<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610530</url>
  </required_header>
  <id_info>
    <org_study_id>2015/S01</org_study_id>
    <nct_id>NCT02610530</nct_id>
  </id_info>
  <brief_title>Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1</brief_title>
  <acronym>SIT-DOWN-1</acronym>
  <official_title>Efficacy of Surgical Intervention for the Treatment of Diabetes Mellitus Type 2 in Overweight Non-responders in Comparison With Conventional Nonsurgical Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkish Metabolic Surgery Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkish Metabolic Surgery Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SIT-DOWN study is a single centered retrospective study in which a total of 90 (ninety)
      participants who are overweight (BMI: 25-29.9 kg/m2) and have type 2 diabetes mellitus (T2DM)
      will be evaluated for the efficacy of surgical intervention in comparison with medical
      treatment. Primary endpoint of the study will be the change in glycemic regulation by the end
      of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of bariatric/metabolic surgery has conventionally been reserved for those whose body-mass
      index (BMI) is 35 kg/m2 or greater. Trials in these morbidly obese patients confirmed the
      benefits in terms of weight loss and provide evidence that surgery can result in remission of
      diabetes, and as a result lead to improvement in cardiovascular risk factors. Within the
      light of these data, there appear to be a shift towards lower BMI, with many advocating it as
      a reasonable option for diabetics with a lower BMI (&lt;30) who have failed other attempts of
      medical treatment. But this approach is limited because of lack of data on the effects of
      surgical outcomes in this group of patients which is the main rationale for this
      retrospective study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in glycated hemoglobin (HbA1c)</measure>
    <time_frame>1 year</time_frame>
    <description>Complete diabetic remission (HbA1c &lt; 6%) and partial diabetic remission (HbA1c= 6-6.5%) without medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension Control</measure>
    <time_frame>1 year</time_frame>
    <description>Systolic blood pressure (BP) &lt;130 mm Hg and diastolic BP &lt;80 mm Hg, without medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL (low-density lipoprotein) Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>&lt;100 mg/dL, without medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL (high-density lipoprotein) Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>&gt;40 mg/dL, without medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>1 year</time_frame>
    <description>&lt;150 mg/dL, without medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Control</measure>
    <time_frame>1 year</time_frame>
    <description>Amount of weight loss in kilograms.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Overweight</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Non-Surgery</arm_group_label>
    <description>Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery-A</arm_group_label>
    <description>Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery-B</arm_group_label>
    <description>Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve Gastrectomy with Ileal Transposition</intervention_name>
    <description>Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.</description>
    <arm_group_label>Surgery-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve Gastrectomy with Transit Bipartition</intervention_name>
    <description>Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.</description>
    <arm_group_label>Surgery-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Treatment</intervention_name>
    <description>Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.</description>
    <arm_group_label>Non-Surgery</arm_group_label>
    <other_name>Oral antidiabetics and / or insulin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Overweight, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI= 25-29.9
        kg/m2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI=
             25-29.9 kg/m2

          -  Participants with baseline HbA1c ≥ % 7.5, not achieved HbA1c &lt; % 7.3 at 3 months on
             therapy

          -  Absence of co-morbidities (neuropathy, retinopathy, cardiovascular disease, stroke
             events or lower extremity amputation).

        Exclusion Criteria:

          -  Liver cirrhosis, severe renal failure, collagen diseases, severe endocrinopathies,
             blindness.

          -  Heart failure, acute myocardial infarction, stroke or transient ischemic attack,
             unstable angina pectoris.

          -  History of malignancy or malignant neoplasm in place, severe inflammatory
             complications, neurological or cardiovascular in act.

          -  Pregnancy

          -  Any conditions that at the discretion of the head of the study can represent risk to
             the participant or could affect the protocol results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alper Celik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish Metabolic Surgery Foundation</affiliation>
  </overall_official>
  <reference>
    <citation>DePaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc. 2009 Aug;23(8):1724-32. doi: 10.1007/s00464-008-0168-6. Epub 2008 Oct 2.</citation>
    <PMID>18830747</PMID>
  </reference>
  <reference>
    <citation>Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S, Kirwan JP, Schauer PR. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond). 2010 Mar;34(3):462-71. doi: 10.1038/ijo.2009.254. Epub 2009 Dec 22.</citation>
    <PMID>20029383</PMID>
  </reference>
  <reference>
    <citation>Finelli C, Padula MC, Martelli G, Tarantino G. Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? World J Gastroenterol. 2014 Nov 28;20(44):16649-64. doi: 10.3748/wjg.v20.i44.16649. Review.</citation>
    <PMID>25469034</PMID>
  </reference>
  <reference>
    <citation>Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, Pothier CE, Brethauer S, Nissen S, Gupta M, Kirwan JP, Schauer PR. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Aug;36(8):2175-82. doi: 10.2337/dc12-1596. Epub 2013 Feb 25.</citation>
    <PMID>23439632</PMID>
  </reference>
  <reference>
    <citation>Santoro S. From Bariatric to Pure Metabolic Surgery: New Concepts on the Rise. Ann Surg. 2015 Aug;262(2):e79-80. doi: 10.1097/SLA.0000000000000590.</citation>
    <PMID>24646534</PMID>
  </reference>
  <reference>
    <citation>Celik A, Ugale S. Functional restriction and a new balance between proximal and distal gut: the tools of the real metabolic surgery. Obes Surg. 2014 Oct;24(10):1742-3. doi: 10.1007/s11695-014-1368-x.</citation>
    <PMID>25027983</PMID>
  </reference>
  <reference>
    <citation>Santoro S, Castro LC, Velhote MC, Malzoni CE, Klajner S, Castro LP, Lacombe A, Santo MA. Sleeve gastrectomy with transit bipartition: a potent intervention for metabolic syndrome and obesity. Ann Surg. 2012 Jul;256(1):104-10. doi: 10.1097/SLA.0b013e31825370c0.</citation>
    <PMID>22609843</PMID>
  </reference>
  <reference>
    <citation>De Paula AL, Stival AR, Halpern A, DePaula CC, Mari A, Muscelli E, Vencio S, Ferrannini E. Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. J Gastrointest Surg. 2011 Aug;15(8):1344-53. doi: 10.1007/s11605-011-1550-6. Epub 2011 May 10.</citation>
    <PMID>21557013</PMID>
  </reference>
  <reference>
    <citation>De Paula AL, Stival AR, Macedo A, Ribamar J, Mancini M, Halpern A, Vencio S. Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2). Surg Obes Relat Dis. 2010 May-Jun;6(3):296-304. doi: 10.1016/j.soard.2009.10.005. Epub 2009 Nov 10.</citation>
    <PMID>20096647</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>metabolic surgery</keyword>
  <keyword>medical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

